Neuronetics представит данные о клинической эффективности ТМС на международном форуме и расширит команду продаж

Компания Neuronetics анонсировала участие руководства в дискуссии о коммерциализации новых препаратов для лечения психических расстройств и представит реальные данные из базы TrakStar на ежегодном собрании общества ТМС. Также на предприятии назначен новый вице-президент по продажам Роберт Грин, обладающий опытом в сфере медицинского оборудования.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

Neuronetics, Inc. (NASDAQ:STIM) is one of the 10 High Growth Stocks Insiders Are Buying. On July 6, 2026, Neuronetics, Inc. (NASDAQ:STIM) announced that management will participate at B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event being held in person at the InterContinental Boston. Neuronetics will participate in a panel discussion titled "Commercializing the Next Wave of Novel Neuropsychiatric Drugs" alongside Compass Pathways on Thursday, July 16, 2026. Management will also be available for one-on-one meetings with institutional investors throughout the day. On June 2, Neuronetics announced its participation as a Silver Sponsor at the 2026 Clinical TMS Society Annual Meeting. The company said real-world data from its proprietary TrakStar database will be featured in an oral presentation and multiple scientific posters focused on transcranial magnetic stimulation for mental health conditions. Chief Technology Officer Cory Anderson said the expansion of real-world evidence is "critical" to advancing the understanding of TMS and its role in clinical practice. create jobs 51/Shutterstock.com Also on June 2, Neuronetics announced that Robert Greene was appointed Senior Vice President of Sales, effective June 1, 2026. Greene brings experience leading commercial strategy and sales organizations within healthcare and medical technology, including capital equipment and service. Neuronetics, Inc. (NASDAQ:STIM) provides in-office treatments for patients with neurohealth disorders in the United States and internationally. While we acknowledge the potential of STIM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.